Physician profile
Arthur T Young
NPI 1235192337
$8,021.24
in general payments reported to CMS, 2019-2025
19 companies · $66.10 in 2025
The $66.10 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,995 · 2020: $1,803 · 2021: $1,957 · 2022: $747 · 2023: $826 · 2024: $627 · 2025: $66.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402 · Entertainment: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.48 |
| Entertainment | $116.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $4,054.27 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $602.53 | 2019-2022 | |
| Coopervision INC. | $442.69 | 2019-2024 | Myday Contact Lens |
| Alcon Vision LLC | $440.25 | 2019-2025 | Clareon |
| Dompe US, INC. | $347.40 | 2021-2024 | Oxervate |
| Optos, INC. | $346.31 | 2020-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $246.25 | 2023-2024 | Infuse Multifocal |
| Maculogix, INC. | $210.73 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $192.39 | 2020-2023 | Acuvue |
| Biotissue Holdings INC. | $181.10 | 2024 | |
| Optovue, INC. | $178.39 | 2019-2021 | |
| Abbvie INC. | $124.97 | 2022 | |
| Sun Pharmaceutical Industries INC. | $121.66 | 2023 | Cequa |
| Regeneron Healthcare Solutions, INC. | $119.16 | 2019 | |
| Astellas Pharma US INC | $101.60 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $100.37 | 2022 | |
| Ocular Therapeutix, INC. | $91.51 | 2022 | |
| Amgen INC. | $84.48 | 2024 | Tepezza |
| Visionix USA, INC | $35.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.